Zhongnan Medical Journal Press

Home Results

A total of 26 result was found. Results that relate to Small cell lung cancer

Efficacy and safety of Tislelizumab combined with chemotherapy in the treatment of non-small cell lung cancer: a Meta-analysis

Published on New Medicine 2025,35(4):442-451.
11825 times 2048 times

WANG Kuan TAN Xiao GUO Yanni

Non-small cell lung cancer Tislelizumab Chemotherapy Effectiveness Safety Meta-analysis
Details
Exploration on medication pattern of traditional Chinese medicine treatment for non-small cell lung cancer based on real world data

Published on Chinese Journal of Pharmacoepidemiology 2025,34(4):398-409.
18108 times 3954 times

LI Junya SHI Yanglin YANG Jianya LI Ya LI Suyun

Non-small cell lung cancer Traditional Chinese medicine Real-word data Latent structure model Association rule Medication pattern
Details
Efficacy and safety of tislelizumab combined with anlotinib in the treatment of advanced non-small cell lung cancer: a Meta-analysis

Published on Chinese Journal of Pharmacoepidemiology 2025,34(7):785-794.
10581 times 1577 times

TENG Xinli LIU Bin XIU Junli ZHOU Xiaohong

Tislelizumab Anlotinib Non-small cell lung cancer Meta-analysis Systematic review
Details
Sugemalimab as first-line treatment for non-small cell lung cancer: a rapid health technology assessment

Published on Chinese Journal of Pharmacoepidemiology 2025,34(7):806-814.
9819 times 1505 times

HOU Yibing KANG Shuo GONG Yuan WANG Xiaohui NIE Ying LIU Huanlong

Sugemalimab Non-small cell lung cancer Effectiveness Safety Economics Rapid health technology assessment
Details
A case report on chemotherapy-free treatment for small cell lung cancer

Published on New Medicine 2025,35(8):974-979.
11159 times 1589 times

Small cell lung cancer Chemotherapy-free Radiotherapy Immunotherapy Targeted therapy
Details
Research progress of LRPPRC in non-small cell lung cancer

Published on New Medicine 2025,35(10):1228-1234.
5968 times 1118 times

LE Sihong ZHANG Qin FANG Weidan KUANG Peng ZHANG Ling

Non-small cell lung cancer LRPPRC Drug resistance Regulation mechanisms Immunotherapy
Details
Research advances in adverse drug reactions and their management in targeted therapy for driver gene-positive advanced non-small cell lung cancer

Published on Chinese Journal of Pharmacoepidemiology 2025,34(11):1320-1329.
5994 times 1033 times

FAN Jiameng PAN Lei

Non-small cell lung cancer Target therapy Adverse drug reactions Symptom management Biomarker
Details
Immune-related hyperglycemia accompanied by optic neuritis in extensive-stage small cell lung cancer: a case report and pharmaceutical management

Published on Chinese Journal of Pharmacoepidemiology 2026,35(1):114-120.
3178 times 721 times

ZHENG Xinyi XU Xin WANG Xiaohang SU Yingjie

Extensive-stage small cell lung cancer Serplulimab Immune-related hyperglycemia Immune-related optic neuritis Immune-related adverse events
Details
Effects of denosumab versus zoledronic acid on bone formation markers and cancer pain intensity in patients with non-small cell lung cancer and bone metastases: a retrospective study

Published on Chinese Journal of Pharmacoepidemiology 2026,35(2):140-146.
3526 times 740 times

HU Ran LI Wei LI Yonghong CHEN Cong WAN Chao

Denosumab Zoledronic acid Non-small cell lung cancer Bone metastases Cancer pain Bone formation markers Retrospective study
Details
Cost-effectiveness analysis of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment for progressed EGFR-mutant non-small-cell lung cancer

Published on Chinese Journal of Pharmacoepidemiology 2026,35(5):553-562.
1445 times 275 times

JIN Lijun ZHANG Lele HAN Lu LYU Zhenye

Sacituzumab tirumotecan Non-small cell lung cancer EGFR mutation Quality adiusted life year Incremental Cost-effectiveness ratio Cost-effectiveness analysis Scenaio analysis
Details
Research progress on multidrug resistance mechanism of non-small cell lung cancer and reversal effect of active ingredients of traditional Chinese medicine

Published on Frontiers in Pharmaceutical Sciences 2026,30(5):857-866.
807 times 148 times

ZHENG Wanrong LAI Fobao

Tumor multidrug resistance Non-small cell lung cancer Active components of traditional Chinese medicine Resistance reversal Non-coding RNA Programmed cell death
Details